Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
The First Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, China.
Biomed Res Int. 2017;2017:1875843. doi: 10.1155/2017/1875843. Epub 2017 Nov 13.
The association between circulating microRNA-375 (miR-375) expression and cancers has been studied; however, the results are inconsistent. We searched PubMed, Embase, and Web of Science for studies concerning the diagnostic value of miR-375 for cancer. The bivariate meta-analysis model was employed to summarize sensitivity, specificity, and diagnostic odds ratio (DOR) for miR-375 in the diagnosis of cancer. Summary receiver operating characteristic (SROC) curve analysis and the area under the curve (AUC) were also used to check the overall test performance. A total of 645 cancer patients and 421 cancer-free individuals from 12 studies were contained in this meta-analysis. The summary estimates revealed that the pooled sensitivity was 78% (95% confidence interval (CI): 64%-87%), the specificity was 74% (95% CI: 62%-84%), the DOR was 10.04 (95% CI: 6.01-16.77), and the AUC was 0.82 (95% CI: 0.79-0.85). In addition, we found that the diagnostic effect of miR-375 varies according to the race and cancer type. Our data suggest that miR-375 profiling has a potential to be used as a screening test for cancers but the specific race and cancer should be considered. More studies on the diagnostic value of miR-375 for cancer are needed in the future.
循环 microRNA-375（miR-375）表达与癌症之间的关联已经得到研究；然而，结果并不一致。我们检索了 PubMed、Embase 和 Web of Science，以获取有关 miR-375 对癌症诊断价值的研究。采用双变量 meta 分析模型来总结 miR-375 对癌症诊断的敏感性、特异性和诊断比值比（DOR）。汇总受试者工作特征（SROC）曲线分析和曲线下面积（AUC）也用于检查总体测试性能。这项荟萃分析共纳入了来自 12 项研究的 645 名癌症患者和 421 名无癌症个体。汇总估计表明，合并敏感性为 78%（95%置信区间[CI]：64%-87%），特异性为 74%（95% CI：62%-84%），DOR 为 10.04（95% CI：6.01-16.77），AUC 为 0.82（95% CI：0.79-0.85）。此外，我们发现 miR-375 的诊断效果因种族和癌症类型而异。我们的数据表明，miR-375 谱分析有可能被用作癌症的筛查试验，但应考虑具体的种族和癌症。未来需要更多关于 miR-375 对癌症诊断价值的研究。
